INJECTION INDEXWeight management, clearly.
The online care edition
October 2026
Offer profile · October 7, 2026

Trimi Review

Trimi explicitly separates an annual monthly equivalent from the upfront bill: semaglutide is advertised at $1,188 for twelve months, with a different month-to-month rate.

Article updated

Read this firstArticle updated November 13, 2026; source dates below

Trimi explicitly distinguishes an annual upfront charge from month-to-month pricing for both medicines.

Semaglutide monthly
$175

Month-to-month plan.

Semaglutide annual
$99

$1,188 upfront for twelve months.

Tirzepatide monthly
$235

Month-to-month plan.

Trimi’s public pricing explanation supplies a detail that many monthly-looking offers leave unclear: its $99 semaglutide figure is an annual-plan equivalent, with $1,188 due upfront for a twelve-month commitment. The month-to-month price is separately listed as $175. These are different purchase models, not interchangeable ways to quote one payment.

The same distinction applies to tirzepatide, advertised at $125 per month on an annual plan billed $1,500 upfront, or $235 month to month. This review keeps that financial clarity alongside the prescription, compounded-product and outcome limitations.

The details, visualized

Trimi: monthly equivalents by medicine and term

Advertised US dollars; billing scope shown on every row

  1. Semaglutide monthly$175

    Month-to-month plan.

  2. Semaglutide annual$99

    $1,188 upfront for twelve months.

  3. Tirzepatide monthly$235

    Month-to-month plan.

  4. Tirzepatide annual$125

    $1,500 upfront for twelve months.

Provider-advertised information checked October 7, 2026. Items can have different inclusions or commitments; read each row before comparing. Calculations are labeled.

View the printable chart imageTrimi: monthly equivalents by medicine and term. The same values and context are available in the data table above.
Research note 01

The lower equivalent has a larger first payment

Trimi’s answers page gives both the annual total and the month-to-month figure. At unchanged monthly prices, twelve semaglutide payments would total $2,100 versus $1,188 upfront; twelve tirzepatide payments would total $2,820 versus $1,500 upfront. Those differences describe payment structures, not the suitability of a year-long treatment commitment.

The annual comparison should include the policy for a medical stop, an unused supply and any refund promise. A reader who might need a different medication or another care arrangement should resolve those rules before treating the arithmetic saving as money they will necessarily retain.

Research note 02

Trial references need their original product context

Trimi’s homepage cites branded-medicine study averages while describing compounded preparations. This publication keeps those references separate: the trial describes the studied product, dose and population; it does not measure the performance of Trimi’s supplied preparation or its service quality.

Before you decide

Questions worth answering

What is the most useful detail to verify before choosing Trimi?

Trimi explicitly distinguishes an annual upfront charge from month-to-month pricing for both medicines. Save the selected product name, payment or supply period, and the source or agreement that confirms it. A written record makes later changes easier to identify.

Does this review establish how much weight I would lose?

No. This is a review of public offer information, including its billing and service model. A provider advertisement, testimonial, or trial of a branded medicine does not establish the outcome of an individual order from Trimi.

Evidence behind this page

Sources & chart notes

Source dates are listed with each document. Earlier research and later offer updates are identified separately. Provider pages establish advertised terms. Labels and trial reports describe specific medicines and study populations. Medical review has not been completed.

Editorial illustration: a telehealth screen, a question card and an unbranded container.
Trimi Review — keep the product information and the route for asking a question in the same comparison.

The annual equivalent is not a monthly charge

Trimi’s answers page states the total upfront amounts and describes no membership, enrollment or shipping fee within those offers. That makes the included-cost presentation relatively concrete. A reader can compare the full commitment rather than assuming the smallest monthly-looking figure is what leaves the account each month.

A year paid upfront also creates a different flexibility question from a month-to-month plan. The published amounts do not by themselves settle every cancellation or unused-term refund circumstance. The renewal guide makes those financial questions visible without assuming the annual offer is always better value.

Editorial illustration: a calculator, an open purchase ledger and an unbranded container.
The annual equivalent is not a monthly charge — compare what the payment covers, when it renews and which charges remain separate.

The price includes a conditional clinical pathway

Trimi describes licensed provider review, pharmacy compounding, supplies and shipping within the price. It names Arora Health as its clinical network and says each prescription is reviewed by a licensed US provider. The actual medication still depends on that professional decision.

The page advertises an automatic refund when its medical team does not approve treatment. That is a specific nonapproval circumstance, distinct from the separate money-back promise connected to weight change. Neither description amounts to a personal eligibility assessment carried out by this publication.

Trial references do not become Trimi outcomes

The homepage names STEP-1, SURMOUNT-1 and SELECT and explicitly says the figures come from active-ingredient trials rather than guaranteeing individual results. That qualification is essential. These are not observed results from a Trimi patient cohort or a study of every compounded prescription it dispenses.

Trimi also states that compounded preparations are not FDA-approved as drugs. A named ingredient study, clinical network and pharmacy process have separate roles. The treatment guide explains why those features do not transfer a branded medicine’s approval to a compounded finished preparation.

Editorial illustration: an open reference book, a magnifying glass and a document.
Trial references do not become Trimi outcomes — follow the source behind a claim as well as the advertised description.

The useful comparison is both financial and clinical

Trimi’s strongest public feature is the explicit upfront-versus-monthly distinction. The open question concerns the complete selected agreement, including continuing terms and how any refund promise works. This review did not purchase an annual plan, authenticate a pharmacy or measure a treatment outcome.

The Fridays review follows a four-month membership promotion, while Henry describes longer-plan balance qualifications. The cost guide connects those commitments. It does not treat an annual equivalent as proof of affordability or suitability for every reader.

Focused comparisons for this offer

See Cheapest semaglutide injection plans: offers with the whole bill visible · Cheapest tirzepatide injection plans: offers beyond the lowest monthly number · Best month-to-month injection-plan comparisons: ways to limit upfront commitment · Best annual GLP-1 plan comparisons and monthly alternatives: payment choices · Best GLP-1 programs when switching providers: routes for a clear handoff.

Compare another model

Embody · CareBox · He & She MD · CoreAge Rx

The invoice guide and product-status guide explain the distinctions behind these entries.

Research record

Documents used

Original references are retained below. Later observations and their source dates are identified in the dated updates and research notes. Advertising describes an offer; it is not independent verification of treatment outcomes.

  1. Trimi: Official information ↗
  2. Trimi: Detailed pricing and treatment answers ↗
  3. FDA: Unapproved GLP-1 drug concerns ↗